Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/173290
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Brasó Maristany, Fara | - |
dc.contributor.author | Griguolo, Gaia | - |
dc.contributor.author | Pascual, Tomás | - |
dc.contributor.author | Paré, Laia | - |
dc.contributor.author | Nuciforo, Paolo | - |
dc.contributor.author | Llombart Cussac, Antonio | - |
dc.contributor.author | Bermejo de las Heras, Begoña | - |
dc.contributor.author | Oliveira, Mafalda | - |
dc.contributor.author | Morales, Serafín | - |
dc.contributor.author | Martínez, Noelia | - |
dc.contributor.author | Vidal Losada, Maria Jesús | - |
dc.contributor.author | Adamo, Barbara | - |
dc.contributor.author | Martínez, Olga | - |
dc.contributor.author | Pernas, Sònia | - |
dc.contributor.author | López, Rafael | - |
dc.contributor.author | Muñoz Mateu, Montserrat | - |
dc.contributor.author | Chic, Núria | - |
dc.contributor.author | Galván, Patricia | - |
dc.contributor.author | Garau, Isabel | - |
dc.contributor.author | Manso, Luis | - |
dc.contributor.author | Alarcón, Jesús | - |
dc.contributor.author | Martínez, Eduardo | - |
dc.contributor.author | Gregorio, Sara | - |
dc.contributor.author | Gomis, Roger R. | - |
dc.contributor.author | Villagrasa, Patricia | - |
dc.contributor.author | Cortés, Javier | - |
dc.contributor.author | Ciruelos, Eva | - |
dc.contributor.author | Prat Aparicio, Aleix | - |
dc.date.accessioned | 2021-01-20T12:24:38Z | - |
dc.date.available | 2021-01-20T12:24:38Z | - |
dc.date.issued | 2020-01-20 | - |
dc.identifier.issn | 2041-1723 | - |
dc.identifier.uri | http://hdl.handle.net/2445/173290 | - |
dc.description.abstract | The HER2-enriched (HER2-E) subtype within HER2-positive (HER2+) breast cancer is highly addicted to the HER2 pathway. However, ∼20-60% of HER2+/HER2-E tumors do not achieve a complete response following anti-HER2 therapies. Here we evaluate gene expression data before, during and after neoadjuvant treatment with lapatinib and trastu- zumab in HER2+/HER2-E tumors of the PAMELA trial and breast cancer cell lines. Our results reveal that dual HER2 blockade in HER2-E disease induces a low-proliferative Luminal A phenotype both in patient's tumors and in vitro models. These biological changes are more evident in hormone receptor-positive (HR+) disease compared to HR-negative disease. Interestingly, increasing the luminal phenotype with anti-HER2 therapy increased sensitivity to CDK4/6 inhibition. Finally, discontinuation of HER2-targeted therapy in vitro, or acquired resistance to anti-HER2 therapy, leads to restoration of the original HER2-E phenotype. Our findings support the use of maintenance anti-HER2 therapy and the therapeutic exploitation of subtype switching with CDK4/6 inhibition. | - |
dc.format.extent | 11 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Nature Publishing Group | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.1038/s41467-019-14111-3 | - |
dc.relation.ispartof | Nature Communications, 2020, vol. 11 | - |
dc.relation.uri | https://doi.org/10.1038/s41467-019-14111-3 | - |
dc.rights | cc-by (c) Brasó Maristany, Fara et al., 2020 | - |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es | - |
dc.source | Articles publicats en revistes (Medicina) | - |
dc.subject.classification | Càncer de mama | - |
dc.subject.classification | Fenotip | - |
dc.subject.other | Breast cancer | - |
dc.subject.other | Phenotype | - |
dc.title | Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.identifier.idgrec | 699865 | - |
dc.date.updated | 2021-01-20T12:24:38Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 31959756 | - |
Appears in Collections: | Articles publicats en revistes (Medicina) Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
699865.pdf | 1.09 MB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License